Table 1

Next steps to address gaps in understanding Ebola virus immunology in the context of regulatory evaluation.

Develop and curate an NHP sample bank that will allow different laboratories to analyze samples from NHPs that were protected versus unprotected from Ebola virus challenge.
Form a clinical assay working group to facilitate standardization of clinical assays among stakeholders.
Evaluate humoral responses as potential immune markers of protection in upcoming clinical trials.
Develop protocols to safely handle and store serum and/or PBMCs from trial participants who may have Ebola infection.
Collect and store samples from as many vaccinees as possible in areas of risk for Ebola exposure in order to aid in establishing an immune marker of protection.